|
The
following potentially dilutive securities have been excluded from the computation of diluted shares of common stock outstanding as they
would be anti-dilutive:
Schedule
of Potentially Dilutive Securities
| |
|
2023 |
|
|
2022 |
|
| |
|
March
31, |
|
| |
|
2023 |
|
|
2022 |
|
| Common
stock warrants August 2021 |
|
|
2,827,708 |
|
|
|
2,827,708 |
|
| Underwriter warrants
August 2021 |
|
|
50,416 |
|
|
|
50,416 |
|
| Private
warrants |
|
|
— |
|
|
|
7,549 |
|
| Chanticleer
warrants |
|
|
1,267 |
|
|
|
1,267 |
|
| Series
C warrants |
|
|
809,243 |
|
|
|
809,243 |
|
| Series
3 warrants |
|
|
276,140 |
|
|
|
— |
|
| Unvested
restricted stock units and awards |
|
|
172,680 |
|
|
|
70,568 |
|
| Common
stock warrants February 2023 |
|
|
27,314,814 |
|
|
|
— |
|
| Underwriter
warrants February 2023 |
|
|
972,222 |
|
|
|
— |
|
| Total
anti-dilutive weighted average shares |
|
|
32,424,490 |
|
|
|
3,766,751 |
|
|